Enlon

Crying, Lazy Eye, Slow Heart Rate + 31 more

Treatment

3 FDA approvals

20 Active Studies for Enlon

What is Enlon

Atropine

The Generic name of this drug

Treatment Summary

Atropine is an alkaloid found in certain plants, such as Atropa belladonna and other members of the solanaceae family.

Lomotil

is the brand name

image of different drug pills on a surface

Enlon Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lomotil

Atropine

1960

151

Approved as Treatment by the FDA

Atropine, otherwise known as Lomotil, is approved by the FDA for 3 uses which include Sinus Bradycardia and Carbamates .

Sinus Bradycardia

Carbamates

Used to treat Toxic effect of organophosphate and carbamate in combination with Pralidoxime

muscarinic side effects

Helps manage muscarinic side effects

Effectiveness

How Enlon Affects Patients

Atropine is a medicine that blocks the effects of acetylcholine, a chemical in the body that causes muscles to contract. It slows down heart rate and can be used to prevent or stop slow or stopped heartbeats caused by choline esters, anticholinesterase agents, or other drugs. It can also lessen the degree of partial heart block caused by choline esters. When put in the eye, it causes the pupil to enlarge. However, it can cause glaucoma, complete urinary retention in people with prostate enlargement, thickening of lung secretions and complete obstruction of the stomach in

How Enlon works in the body

Atropine blocks the effects of acetylcholine, a chemical that helps nerves send signals. It works by binding to and blocking certain types of nerve receptors in the body, such as those found in muscles and the heart. This stops acetylcholine from working properly. Atropine's effects can be reversed by increasing the amount of acetylcholine in the body.

When to interrupt dosage

The advised measure of Enlon is contingent upon the determined condition, such as Bronchospasm, Bile fluid and Muscle Hypertonia. The amount of dosage fluctuates as per the technique of delivery (e.g. Oral or Injection - Intramuscular) detailed in the below table.

Condition

Dosage

Administration

Crying

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Lazy Eye

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Slow Heart Rate

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Cholinesterase Inhibitors

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Kidney Calculi

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

laughing

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

dobutamine stress echocardiography

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

muscarinic side effects

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

prophylaxis of Bradycardia

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Bronchial Spasm

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Poisoning

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Pylorospasm

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Parkinson Disease

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Organophosphorus Compounds

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

induction of Cycloplegia

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Intestines, Small

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Induced Hyperthermia

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Rhinorrhea

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Spasm

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Urinary Tract Infections

0.025 mg, , 0.0194 mg/mL, 0.1 mg/mL, 0.0194 mg, 1.0 mg/mL, 4.0 mg/mL, 0.4 mg/mL, 10.0 mg/mL, 0.05 mg/mL, 0.14 mg/mL, 0.0582 mg, 0.4 mg, 0.6 mg, 1.0 %, 0.1 mg, 10.0 mg, 0.8 mg, 0.3 mg, 1.0 mg, 3.0 mg, 0.0097 mg, 0.025 mg/mL, 5.0 mg/mL, 20.0 mg/mL, 2.5 mg/mL, 0.5 mg, 0.01 mg/mg, 0.019 mg/mL, 21.0 mg/mL, 0.03 mg, 0.6 mg/mL, 0.00194 mg/mL, 0.8 mg/mL, 0.3 mg/mL, 0.5 mg/mL

, Tablet, Elixir, Elixir - Oral, Oral, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramuscular; Intravenous; Subcutaneous, Endotracheal; Intramuscular; Intravenous; Subcutaneous, Parenteral, Injection, Injection - Parenteral, Injection - Intramuscular; Intravenous; Subcutaneous, Solution - Ophthalmic, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Intramuscular, Injection, solution - Intramuscular, Intravenous, Injection, solution - Intravenous, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution - Intramuscular; Intravenous; Subcutaneous, Tablet, extended release, Tablet, extended release - Oral, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Ointment, Ointment - Ophthalmic, Capsule, Capsule - Oral, Liquid - Oral, Solution - Oral, Injection - Intramuscular, Kit, Kit - Intramuscular, Respiratory (inhalation), Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Injection, solution - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous, Intravenous; Parenteral, Injection - Intravenous; Parenteral, Injection - Intravenous, Injection - Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous

Warnings

Enlon has fourteen contraindications and should not be taken in the presence of the conditions listed in the following table.

Enlon Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Uterine Inertia

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

unstable cardiovascular status

Do Not Combine

Rapid Heartbeat

Do Not Combine

Chronic Kidney Disease (CKD)

Do Not Combine

Arterial Occlusive Diseases

Do Not Combine

Uterine Inertia

Do Not Combine

Uropathy Obstructive

Do Not Combine

Ulcerative Colitis

Do Not Combine

Ulcerative Colitis

Do Not Combine

Tissue Adhesions

Do Not Combine

Myasthenia Gravis

Do Not Combine

There are 20 known major drug interactions with Enlon.

Common Enlon Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Atropine is combined with Aclidinium.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Atropine is combined with Asenapine.

Enlon Toxicity & Overdose Risk

Taking too much atropine can cause a rapid heartbeat, dilated pupils, difficulty swallowing, sweating, dizziness, restlessness, and trembling. In severe cases, this can lead to hallucinations, delirium, coma, and even death due to paralysis and lack of breathing. If someone overdoses on atropine, supportive care should be given, such as oxygen if breathing is affected and cooling methods if there is a fever. Urinary output must be monitored and increased if necessary, and the room should be darkened if needed. A short-acting barbiturate or diazepam may be given to control excitement and convulsions

image of a doctor in a lab doing drug, clinical research

Enlon Novel Uses: Which Conditions Have a Clinical Trial Featuring Enlon?

At present, 22 active trials are underway to ascertain the potential of Enlon for Rhinorrhoea amelioration, Bradycardia prophylaxis and Slow heart rate moderation.

Condition

Clinical Trials

Trial Phases

Slow Heart Rate

2 Actively Recruiting

Not Applicable

hypermobility of the colon

0 Actively Recruiting

Sinus Bradycardia

0 Actively Recruiting

Kidney Calculi

0 Actively Recruiting

Excessive bronchial secretion

0 Actively Recruiting

dobutamine stress echocardiography

0 Actively Recruiting

Intestines, Small

0 Actively Recruiting

Bile fluid

1 Actively Recruiting

Not Applicable

Carbamates

0 Actively Recruiting

Induced Hyperthermia

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

Crying

0 Actively Recruiting

Intubation (procedure)

0 Actively Recruiting

Cycloplegia

0 Actively Recruiting

Poisoning by parasympathomimetics (cholinergics)

0 Actively Recruiting

Urinary Bladder, Overactive

0 Actively Recruiting

Lazy Eye

13 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

induction of Cycloplegia

0 Actively Recruiting

Urinary Tract Infections

7 Actively Recruiting

Not Applicable, Phase 4

Cholinesterase Inhibitors

0 Actively Recruiting

Enlon Reviews: What are patients saying about Enlon?

1

Patient Review

9/8/2011

Enlon for Diagnostic Test for Myasthenia Gravis

Unfortunately, this treatment caused me to have double vision for three weeks. I'm glad the neurologist was able to use Enlon to diagnose my condition (myasthenia gravis) but immediately after the IV injection, I passed out. It was a scary experience.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about enlon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Edrophonium an antidote for?

"DB01010 is a cholinesterase inhibitor used to treat cardiac arrhythmias and myasthenia gravis. It has also been used as an antidote to curare."

Answered by AI

What is the drug pyridostigmine used for?

"Pyridostigmine is used to treat myasthenia gravis, a condition that causes muscle weakness."

Answered by AI

What is Edrophonium used for?

"Edrophonium injection is used to help diagnose myasthenia gravis (severe muscle weakness) and to help select the proper treatment for the disease. Edrophonium may also be used to reverse the effects of certain muscle relaxants (eg, gallamine, tubocurarine)."

Answered by AI

What is Enlon Plus used for?

"SLIDESHOW: ENLON-PLUS (edrophonium chloride and atropine sulfate) is recommended as a reversal agent or antagonist for nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents."

Answered by AI

Clinical Trials for Enlon

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Medstar National Rehabilitation Hospital in Washington D.C., United States.

Lactobacillus Crispatus for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC). If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome. Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

Phase < 1
Recruiting

Medstar National Rehabilitation Hospital

Suzanne Groah, MD

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD

Have you considered Enlon clinical trials?

We made a collection of clinical trials featuring Enlon, we think they might fit your search criteria.
Go to Trials
Image of Mayo Clinic in Rochester, United States.

Stent Placement for Gallbladder Disorders

18 - 95
All Sexes
Rochester, MN

This randomized trial will look at whether placing two cystic duct stents is more effective than one cystic duct stent in preventing recurrent gallbladder disease (cholecystitis, gallstone pancreatitis, or biliary colic) among patients who are not immediate surgical candidates for removal of their gallbladder. The study will evaluate the safety profile, including rates of recurrent cholecystitis, biliary colic, and procedure-related complications, and technical success, defined as successful placement of stents into the gallbladder. The main questions it aims to answer are: 1. Does placement of two transpapillary cystic duct stents reduce the risk of recurrent symptomatic gallbladder disease compared to one stent? 2. Is there a difference in procedure-related adverse events (post-ERCP pancreatitis, cholangitis, stent migration) between the two strategies? Researchers will compare outcomes between patients randomized to one stent versus two stents to determine which approach provides better long-term gallbladder drainage and fewer recurrent events. Participants will: Be evaluated for eligibility and provide informed consent prior to undergoing an endoscopic retrograde cholangiopancreatography (ERCP), an endoscopy where a guidewire is placed into the bile duct from the small intestine. They will then undergo ERCP with transpapillary cystic duct stent placement, randomized to one or two stents. All participants will receive standard post-procedure care and follow-up assessments for recurrence, adverse events, and need for reintervention.

Recruiting
Has No Placebo

Mayo Clinic

Eric Vargas

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA

At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.

Waitlist Available
Has No Placebo

UPMC Magee-Womens Hospital

Anna Binstock, MD

Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits

Phase 4
Waitlist Available

University of California, San Francisco

Alexandra Bicki, MD

Have you considered Enlon clinical trials?

We made a collection of clinical trials featuring Enlon, we think they might fit your search criteria.
Go to Trials
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ

Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.

Recruiting
Has No Placebo

Atlantic Health

Image of Vanderbilt University Medical Center in Nashville, United States.

Augmented Pacing for Bradycardia

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if backup pacing at an increased rate improves hemodynamics in adults with relative bradycardia, a permanent pacemaker, and cardiogenic shock. The main question it aims to answer is: Does increasing the backup pacing rate to 100 beats per minute lead to improved cardiac index compared to a backup pacing rate of 75 beats per minute Participants who are already hospitalized in the Cardiovascular Intensive Care Unit with a permanent pacemaker and pulmonary artery catheter in place will be enrolled in this study. Participants will be exposed to each pacemaker rate in a randomized order with hemodynamics assessed after 10 minutes at each rate.

Recruiting
Has No Placebo

Vanderbilt University Medical Center

Image of Midwestern University Eye Institute in Downers Grove, United States.

Noninvasive Brain Stimulation for Lazy Eye

18 - 55
All Sexes
Downers Grove, IL

The goal of this randomized controlled trial is to investigate the effectiveness of non-invasive brain stimulation in treating adults with amblyopia. The main questions it aims to answer are: 1. What are the effects of non-invasive brain stimulation on neuronal plasticity in the visual cortex of adults with amblyopia, and does it produce lasting changes? 2. Do cumulative sessions of non-invasive brain stimulation influence neural plasticity and higher-order visual functions in adults with amblyopia? The investigators hypothesize that non-invasive brain stimulation will show a positive cumulative effect after five (5) consecutive days of stimulation on visual perception and function in adults with amblyopia. Participants will be randomized into one of two treatment groups: 1. High-frequency transcranial random noise stimulation (hf-tRNS). 2. Sham stimulation. Researchers will compare baseline measurements of crowded visual acuity, contrast sensitivity, stereoacuity, phosphene thresholds, global motion perception, form pattern recognition and pattern-reversal visual evoked potentials (VEPs) to post-treatment measurements for each group.

Recruiting
Paid Trial

Midwestern University Eye Institute

Image of Boston Children's Hospital Waltham in Boston, United States.

Dichoptic Treatment for Lazy Eye

8 - 12
All Sexes
Boston, MA

Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.

Phase 3
Recruiting

Boston Children's Hospital Waltham (+52 Sites)

Marjean T Kulp, OD

Have you considered Enlon clinical trials?

We made a collection of clinical trials featuring Enlon, we think they might fit your search criteria.
Go to Trials